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Clinical trial remuneration: the patients’ perspective
Lesley Burgess, Nicky Sulzer, Shaunagh Emanuel
To the Editor: The remuneration of patients in clinical trials is 
controversial because money may influence their decision to 
participate. When the amount becomes irresistible, it represents 
undue inducement and may persuade patients to participate 
in a clinical trial or resist discontinuation against their better 
judgement, which can potentially compromise the informed 
consent process and the scientific validity of the trial.1 This is 
particularly relevant in South Africa, where the potential to 
exploit vulnerable communities readily exists.2
The task of creating guidelines to assist the clinical trial 
industry in deciding what remuneration, if any, trial patients 
should receive is fraught with complexities. Regulatory 
authorities provide general recommendations cautioning 
against undue inducement, but no guidance on when money is  
not due, or how much money constitutes undue inducement.1 
The Council for International Organisations of Medical 
Sciences (CIOMS) gives the most comprehensive guideline, 
stating that ‘ … subjects may be paid for inconvenience and 
time spent and should be reimbursed for expenses incurred, 
in connection with their participation in research’.1,3 South 
Africa’s Medicines Control Council (MCC) stipulates that all 
Phase II - IV clinical trial participants receive R150 per study 
visit – which has been much criticised by the local research 
community.
Methods
Our study aimed to (i) document the opinions of trial 
participants regarding remuneration in clinical trials, and (ii) 
clarify the amount of money that would represent an undue 
inducement to a South African clinical trial patient.
The study was conducted by TREAD Research, a clinical 
trial unit located within Tygerberg Hospital, Parow. Patients 
attending the unit between January 2005 and May 2006 
were approached to participate. The study was approved 
by Stellenbosch University’s Ethics Committee. Consenting 
patients completed an anonymous validated questionnaire 
in their home language. Patients were assigned a random 
consecutive number, and no identifying data were recorded 
on the questionnaire.  Patients were asked to provide basic 
demographic data, level of completed school education, current 
occupation, monthly earnings, health care system used (state 
or private) and method of transport to the study visits. Patients 
were also asked questions regarding their remuneration 
and for what purpose they used it. Data were entered into a 
spreadsheet programme by an independent data capturer. All 
data were analysed by means of Statistica Software Version 7.0 
( StatSoft, Inc., USA).
Results
A total of 250 patients completed the questionnaire. The mean 
(±SD) age of subjects was 56.3 ±10.9 years. The majority of 
the respondents were Afrikaans (71.7%). There were 118 male 
subjects (47.0%) and 132 female subjects (52.6%). Unemployed 
respondents comprised 66.5%, with only 31.5% registering a 
paying job. The median (lower; upper quartile) monthly family 
income was R1 800 (R740; R5 200). Of the respondents, 34.0% 
had completed grade 12 (Matric), 40.6% received after school 
training, and 12.4% had a university education. Sixty-four per 
cent were solely dependent on the public heath care system, 
15.1% had private health care, and 18.7% made use of both 
public and private heath care. Modes of transport to the clinic 
were private car (60.7%), taxi (25.6%), train (7.2%) and bus 
(6.5%). 
Seventy-four per cent of trial participants felt that they 
should receive payment for their clinic visits, yet 93.6% 
indicated that they would still participate in a clinical trial if 
they received no payment. Ninety-four per cent indicated that 
they would not hide details regarding their medical history in 
order to participate in a trial. The amount of R150 would not 
tempt 90.0% of participants to withhold information about 
their true state of health in order to participate in a study. 
Ninety-one per cent indicated that payment was not used by 
the investigator as encouragement to participate in a clinical 
trial.
Regarding why they felt they should be paid for 
participating in a clinical trial, 72.9% responded that payment 
should be made to cover travel expenses, 13.9% that it was an 
incentive to participate, and 13.1% that it covered time spent 
(Fig. 1). Regarding their use of the remuneration, 88.8% of 
subjects reported using it for travel expenses, 7.2% for nothing 
specific, and 6.4% for necessities (Fig. 2).
Of this study population, 64.1% depended solely on the state 
health care system. Only 34.0% had completed grade 12, and 
66.5% were unemployed. Despite these facts, most respondents 
(93.6%) indicated that they would still participate in a clinical 
trial if they received no payment.
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Discussion
The most common reasons for our patients participating in 
clinical trials included contributing to scientific understanding, 
learning about their condition, achieving a sense of belonging, 
and having access to services that they would otherwise be 
unable to afford (Burgess et al., unpublished data). In addition, 
80% of respondents did not think clinical trial participation was 
an easy way to obtain money.
Our study revealed that trial participants believed that they 
should receive remuneration to compensate for travel expenses 
and time spent (Fig. 1). The majority of respondents used the 
remuneration to cover transport costs (Fig. 2). This echoes the 
CIOMS guidelines.3
Blanket compensation, such as that mandated by the MCC, is 
contentious in light of these findings as it does not consider the 
complexities of the clinical trial setting. These include the phase 
and design of the study, disease under study, study subject and 
the fact that money means different things to different people. 
A phase I study, where healthy volunteers often undergo 
repeated phlebotomy and exposure to highly experimental 
treatments, cannot be compared with a phase IV post-
marketing study. A patient suffering from a life-threatening 
condition may make health decisions based on different criteria 
to the otherwise well patient with mild seasonal asthma. In 
making decisions on matters of health, wealthy employed 
participants with medical insurance are unlikely to use the 
same criteria as poorly educated, unemployed participants, 
who are reliant on state health care. Finally, although many 
may agree that money represents an inducement, it is not clear 
what amount of money constitutes undue inducement.1
How the MCC reached their decision that trial participants 
receive R150 per study visit is unclear. However, it is 
necesssary to contextualise this amount of money to 
understand what it means to a trial participant in this country. 
The average study visit takes approximately 2 hours, which 
effectively means that clinical trial patients receive R75 per 
hour for their participation. However, the average South 
African salary is currently R51 per hour.4 The median (first, 
third quartile) hourly income of these study participants was 
R10.23 (R4.10, R29.54).
These figures highlight the potential for undue inducement. 
Most guidelines simply caution against ‘undue inducement’ 
but do not describe when or how much money constitutes 
undue inducement. The Belmont Report states that ‘… undue 
influence occurs through an offer of an excessive, unwarranted, 
inappropriate or improper reward or other overture in order to 
obtain compliance’.5 The majority of respondents in the present 
study indicated that they would not hide details regarding 
their medical history to qualify for a trial, and that the amount 
of R150 would not tempt them to withhold information about 
their true state of health. Furthermore, according to these 
respondents, investigators did not use payment to encourage 
trial participation.
These results therefore suggest that R150 does not constitute 
an undue inducement as it does not compromise participants’ 
integrity or freedom of choice and ability to give voluntary 
consent. However, in the South African context of an average 
hourly salary of R51, the amount of R150 may be considered an 
‘… excessive and unwarranted reward’, as cautioned against.5 
We also found that the majority of trial participants were of 
the opinion that remuneration should be provided for travel 
expenses and time spent at the study visit. This contradicts the 
concept of a blanket compensation rate for trial participation 
and also questions for what purpose patients in this country 
are remunerated.
Generalisations regarding trial reimbursement for clinical 
trial participation are clearly impossible. This study indicates 
that remuneration should be calculated individually for travel 
expenses and time. Instead of stipulating their generalised 
and ostensibly unjustifiable remuneration fee, the regulatory 
authority could offer a written policy guideline advocating the 
purpose and intention of clinical trial remuneration. Clinical 
trialists could then customise this policy on an individualised, 
per patient basis. The challenge remains to find a remuneration 
figure which is not excessive and thereby does not constitute 
Fig. 2. Subjects’ responses to what they use their remuneration for 
(N=286), presented as a percentage of total respondents.
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Fig. 1. Subjects’ responses to why they felt that they should be paid (N=194), presented
as a percentage of total respondents.
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Fig. 2. Subjects’ responses to what they use their remuneration for (N=286),
presented as a percentage of total respondents.
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Fig. 2. Subjects’ responses to what they use their remuneration for (N=286),
presented as a percentage of total respondents.
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undue inducement, while at the same time protecting against 
exploitation of vulnerable communities who are involved in 
clinical research in this country.
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Falsely elevated plasma creatinine levels as a marker of 
nitromethane poisoning
Pieter Ernst Boshoff, Karen Gailey, Mohammed Rafique Moosa 
To the Editor: We report 6 cases of accidental nitromethane 
poisoning, of which there are only 4 reported cases in 
the world literature. The significance of this poisoning 
is that nitromethane interacts with the widely used Jaffe 
reaction method of determining plasma creatinine values. 
The enzymatic creatinine assay method and cystatin C 
determinations are not yet widely available in South African 
laboratories. The resulting, falsely elevated plasma creatinine 
values, which can be very high, can be misinterpreted by 
clinicians as a marker of severe renal failure and could lead 
to inappropriate management. We also report the first known 
death following nitromethane ingestion-induced status 
epilepticus.  
Case report
Six homeless people presented at a regional hospital in the 
Western Cape. They had all ingested unknown quantities of the 
liquid contents of a discarded wine bottle.
The index patient was a 34-year-old man who presented to 
the emergency department having suffered three generalised 
tonic-clonic seizures. He had a Glasgow Coma Score of 9/15, 
blood pressure 110/70 mmHg, pulse rate 62/min, respiratory 
rate 24/min, finger-prick glucose test 13 mmol/l and oxygen 
saturation 94% on room air. He was markedly agitated 
and initially displayed paranoid delusions.  He had status 
epilepticus and was treated with intravenous diazepam (a 
total of 40 mg in 12 hours), phenytoin 1 500 mg and later 
phenobarbitone 1 000 mg. Failing to respond to treatment, he 
was transferred to the intensive care unit (ICU) of the central 
hospital for ventilation. Co-amoxiclav was prescribed for 
possible aspiration pneumonia, and he was maintained on 
a diazepam infusion for the convulsions. Later he required 
inotropic support for haemodynamic instability and a 
thiopentone infusion for control of seizures. A lumbar puncture 
and contrasted computed tomography (CT) scan showed no 
abnormalities. His urine output remained more than  
1 ml/kg/h during admission. He deteriorated progressively, 
developed diabetes insipidus, and was declared brain-dead 11 
days later.
Initial arterial blood gas analysis revealed methaemoglobi-
naemia (blood methaemoglobin level 2.6 g/dl) with arterial 
saturation of 95% on FiO2 40%; blood results were plasma Na 
137 mmol/l, plasma K 4.4 mmol/l, plasma urea 8.6 mmol/
l, and plasma creatinine 10 122 μmol/l. The spontaneous 
decrease in plasma creatinine levels of the index patient is 
shown in Fig. 1.
The 5 other intoxicated patients all suffered severe visual 
hallucinations and paranoid delusions upon admission but 
their clinical examinations and vital signs were all normal. 
Each patient received saline infusions of 100 ml/h to maintain 
an adequate urine output of more than 1 ml/kg/h. They 
also received haloperidol 10 mg and clonazepam 2 mg with 
minimal effect on their mental status. Three of these patients 
had a single tonic-clonic seizure each, responding well to 
intravenous diazepam. All the patients received a loading dose 
of phenytoin of 1 500 mg. The psychotic symptoms dissipated 
by day 3. These patients’ presenting creatinine values were 
6 377 μmol/l, 3 531 μmol/l, 2 971 μmol/l, 3 212 μmol/l, and 
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